APO-RIVASTIGMINE PATCH 10 rivastigmine 9.5 mg/24 hours transdermal drug delivery system sachet

Land: Australien

Sprache: Englisch

Quelle: Department of Health (Therapeutic Goods Administration)

Wirkstoff:

rivastigmine, Quantity: 18 mg

Verfügbar ab:

Arrotex Pharmaceuticals Pty Ltd

INN (Internationale Bezeichnung):

Rivastigmine

Darreichungsform:

Drug delivery system, transdermal

Zusammensetzung:

Excipient Ingredients: acrylates copolymer; ethyl acetate; methylated trimethylated silica; hexane; 2-ethylhexyl acrylate; methyl acrylate; acrylic acid; acrylates/ethylhexyl acrylate copolymer

Verabreichungsweg:

Transdermal

Einheiten im Paket:

7 transdermal drug delivery systems, 30 transdermal drug delivery systems

Verschreibungstyp:

(S4) Prescription Only Medicine

Anwendungsgebiete:

APO-RIVASTIGMINE is indicated for the treatment of patients with mild to moderate dementia of the Alzheimer's type.

Produktbesonderheiten:

Visual Identification: Circular 10cm2 transdermal patch, tri-layer adhesive matrix, translucent white backing film labelled with "Rivastigmine 9.5 mg/24 h"; Container Type: Sachet; Container Material: Other composite material; Container Life Time: 24 Months; Container Temperature: Store below 25 degrees Celsius

Berechtigungsstatus:

Licence status A

Berechtigungsdatum:

2016-01-12